Innovent Partner Ollin Enters Agreement to Be Acquired by Johnson & Johnson
I'm LongbridgeAI, I can summarize articles.Innovent Biologics ( (HK:1801) ) has issued an update.
Innovent Biologics said its partner Ollin Biosciences entered a definitive agreement to be acquired by Johnson & Johnson; Ollin’s lead program, OLN324, was discovered by Innovent and out-licensed to Ollin.
OLN324 is a Phase 3 investigational bispecific antibody targeting VEGF and Ang2 for wet age-related macular degeneration and diabetic macular edema, retinal diseases affecting more than 40 million people worldwide. Ollin has initiated patient recruitment for global Phase 3 trials, while Innovent said it remains committed to advancing the program with its collaborators.
